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Background: Chemotherapy plus bevacizumab is a standard option for ﬁrst-line treatment in metastatic colorectal
cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after com-
pleting ﬁrst-line chemotherapy.
Patients and methods: In an open-label, phase III multicentre trial, patients with mCRC without disease progres-
sion after 4–6 months of standard ﬁrst-line chemotherapy plus bevacizumab were randomly assigned to continuing
bevacizumab at a standard dose or no treatment. CT scans were done every 6 weeks until disease progression. The
primary end point was time to progression (TTP). A non-inferiority limit for hazard ratio (HR) of 0.727 was chosen to
detect a difference in TTP of 6 weeks or less, with a one-sided signiﬁcance level of 10% and a statistical power of
85%.
Results: The intention-to-treat population comprised 262 patients: median follow-up was 36.7 months. The median
TTP was 4.1 [95% conﬁdence interval (CI) 3.1–5.4] months for bevacizumab continuation versus 2.9 (95% CI 2.8–3.8)
months for no continuation; HR 0.74 (95% CI 0.58–0.96). Non-inferiority could not be demonstrated. The median
overall survival was 25.4 months for bevacizumab continuation versus 23.8 months (HR 0.83; 95% CI 0.63–1.1;
P = 0.2) for no continuation. Severe adverse events were uncommon in the bevacizumab continuation arm. Costs for
bevacizumab continuation were estimated to be ∼30 000 USD per patient.
Conclusions: Non-inferiority could not be demonstrated for treatment holidays versus continuing bevacizumab
monotheray, after 4–6 months of standard ﬁrst-line chemotherapy plus bevacizumab. Based on no impact on overall
survival and increased treatment costs, bevacizumab as a single agent is of no meaningful therapeutic value. More ef-
ﬁcient treatment approaches are needed to maintain control of stabilized disease following induction therapy.
Clinical trial registration:: ClinicalTrials.gov, number NCT00544700.
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investigating the optimum duration of polychemotherapy regi-
mens in the ﬁrst-line setting indicate, however, that overall sur-
vival (OS) is not signiﬁcantly different for intermittent versus
continuous treatment [1].
Bevacizumab, a monoclonal antibody that inhibits the
binding of vascular endothelial growth factor to its receptors,
improves the outcome in patients with mCRC when added to
ﬁrst- or second-line chemotherapy, as demonstrated in several
studies [2–6]. In these trials, it was intended to continue chemo-
therapy and bevacizumab until intolerable toxicity or disease
progression. The MACRO trial investigated the effectiveness of
maintenance treatment with single-agent bevacizumab after six
cycles of induction chemotherapy with XELOX + bevacizumab,
versus uninterrupted treatment with XELOX + bevacizumab [7].
This study was designed to investigate the question of chemo-
therapy duration, in an attempt to maintain treatment efﬁcacy
and minimize side-effects, in the context of uninterrupted beva-
cizumab treatment in both arms. Although the prespeciﬁed stat-
istical criteria for non-inferiority of shorter chemotherapy were
not met, there were no statistically signiﬁcant differences in re-
sponse rates (RR), nor in the median progression-free survival
(PFS) or OS. Until now, there are no data available on the
optimal duration for bevacizumab in the ﬁrst-line treatment.
Our trial was designed to assess the efﬁcacy of continuing treat-
ment with single-agent bevacizumab, compared with no con-
tinuation, in patients achieving disease control with induction
therapy consisting of chemotherapy plus bevacizumab.
patients andmethods
eligibility criteria
Eligible patients were aged ≥18 years with pathologically conﬁrmed metastatic
colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance
status 0–1, and had stable disease (SD), partial response (PR) or complete re-
sponse (CR) after the end of ﬁrst-line induction treatment. Induction treat-
ment comprised a standard chemotherapy with a ﬂuoropyrimidine agent,
alone or in combination with irinotecan or oxaliplatin, plus a standard dose of
bevacizumab, for 16–24 weeks. Serum creatinine <177 µmol/l and proteinuria
<2+ were required. The last bevacizumab dose had to be given within 4 weeks
before randomization. Key exclusion criteria included anticipation of the need
for major surgery, e.g. resection or ablation of metastases, concurrent treat-
ment with experimental drugs, clinical symptoms or history of central
nervous system metastases and any serious underlying medical condition that
could impair the ability of the patient to participate in the trial.
study design and treatment
SAKK 41/06 was a prospective, randomized, open-label, phase III trial con-
ducted at 26 sites in Switzerland. Institutional review boards at participating
centres and health authorities approved the protocol. The study followed the
Declaration of Helsinki and Good Clinical Practice guidelines. All patients
provided written informed consent. Randomization was stratiﬁed according to
best response during induction treatment (CR, PR or SD), duration of induc-
tion treatment (16–20 versus 21–24 weeks), type of chemotherapy (irinotecan
combination versus oxaliplatin combination versus ﬂuoropyrimidine only),
disease burden (one organ versus multiple organs with metastasis) and centre.
randomization and masking
Patients were randomly assigned in a 1:1 ratio to receive treatment with either
bevacizumab 7.5 mg/kg intravenously every 3 weeks or no anti-tumour
treatment in this open-label study. During the continuation treatment
period, bevacizumab was to be withdrawn deﬁnitively in the case of symp-
tomatic deterioration, unacceptable toxicity, or major surgery, or if bevacizu-
mab treatment was delayed for more than 4 weeks, calculated from the time
of scheduled treatment. Patients in both arms were transferred to the follow-
up phase after diagnosis of PD or start of second-line treatment.
assessments
A medical history, physical examination, routine blood and urine analysis,
and a pregnancy test for women aged <50 years, were carried out within
2 weeks of study entry. Tumour measurements (CT or MRI scans) were taken
within 21 days before start of the study and were repeated every 6 weeks
during the ﬁrst 30 weeks and every 9 weeks thereafter. Scheduled clinical
visits were carried out every 3 weeks in both arms. Patients who discontin-
ued treatment before PD were assessed for tumour status until progression.
After PD had been documented, patients were followed up for survival data
and for subsequent cancer treatments.
Predeﬁned toxicity related to bevacizumab (gastrointestinal perforation,
bleeding/haemorrhage, hypertension, proteinuria and venous/arterial
thromboembolism) was assessed every 3 weeks and graded according to the
National Cancer Institute Common Toxicity Criteria for Adverse Events
(version 3.0).
statistics
The primary end point was time to progression (TTP), which was deﬁned as
the interval from the date of random assignment until PD or death due to
tumour. Secondary end points included OS, PFS (deﬁned as the time from
start of ﬁrst-line treatment until PD or death), time to second-line treatment
(deﬁned as the time from randomization until start of a new line of cancer
treatment), adverse events and treatment costs.
Assuming a median TTP of at least 16 weeks for patients without bevaci-
zumab continuation and a maximum of 22 weeks for patients with bevacizu-
mab continuation, as well as a prespeciﬁed non-inferiority limit for the
hazard ratio (HR) of 0.727 (16/22 weeks), 219 events were required for a one-
sided signiﬁcance level of 10% and a statistical power of 85% to detect an HR
of 1, including one interim analysis to stop in the case of non-inferiority or to
rule out futility. Non-inferiority was determined based on the O’Brien and
Fleming boundary shape calculated by East 5.4. (Cytel Inc., Cambridge,
MA). Survival curves were estimated using the Kaplan–Meier method and
compared using the log-rank test. The univariate Cox regression models were
carried out to explore the effect of bevacizumab on TTP in various patient
subgroups. This study was registered with ClinicalTrials.gov, number
NCT00544700. Statistical analyses were carried out with SAS 9.2 (SAS
Institute Inc., Cary, NC) and S-Plus 8.1 (TIBCO Software, Palo Alto, CA).
cost analysis
The cost analysis included costs for bevacizumab acquisition, drug administra-
tion, control visits to oncologist every 3 weeks, in-patient care, and X-ray/CT/
MRI scans during the trial phase (supplementary Table S1, available at Annals
of Oncology online). Costs for laboratory tests, outpatient treatment of adverse
events and other outpatient care were not included in the cost analysis.
Overall, treatment costs per patient, as well as treatment cost per month for
the time until progression, were calculated. As costs for control visits and hos-
pital stay may vary substantially, but the exact variation is unknown, we also
conducted a sensitivity analysis estimating costs using low and high (±30% of
base case costs) unit costs for these two parameters. Differences in overall costs
per patient, as well as costs per month (until progression) per patient, between
treatment arms were explored using the Wilcoxon rank-sum test. Multivariate
gender- and age-adjusted comparison was also conducted using a generalized
linear model (gamma distribution, log link).
 | Koeberle et al. Volume 26 | No. 4 | April 2015
original articles Annals of Oncology
results
patient characteristics and treatment
administration
Between October 2007 and May 2012, 265 patients were
included at 26 sites in Switzerland and 262 were randomly
assigned to bevacizumab continuation (n = 131) or no bevacizu-
mab continuation (n = 131) (supplementary Figure S1, available
at Annals of Oncology online). Three patients with PD after the
end of ﬁrst-line chemotherapy were excluded. Baseline demo-
graphic and clinical characteristics were balanced between the
treatment arms (Table 1).
Two patients randomly assigned to the bevacizumab continu-
ation arm did not receive any study treatment: one patient died
without treatment and one patient refused treatment. These
patients were included in the intention-to-treat analysis. The
per-protocol analysis excluding these two patients yields virtual-
ly the same results.
Patients in the bevacizumab continuation arm received a
median of six cycles (range 1–49 cycles). The median bevacizu-
mab dose was 7.5 mg/kg.
efﬁcacy
The median follow-up time using the reversed Kaplan–Meier
method was 36.7 months (range in surviving patients 4.7–60.6
months). The median TTP in the bevacizumab continuation
arm was 4.1 [95% conﬁdence interval (CI) 3.1–5.4] versus 2.9
(95% CI 2.8–3.8) months in the no bevacizumab continuation
arm (HR 0.74; 95% CI 0.58–0.96) (Figure 1). The observed
HR lies close to the non-inferiority margin of 0.727, and non-
inferiority could not be demonstrated (pNI = 0.44). Prespeciﬁed
subgroup analyses were generally consistent with the primary
ﬁndings (Figure 2).
Table 1. Baseline patient demographics and clinical characteristics
Bevacizumab continuation
(n = 131)
No bevacizumab continuation
(n = 131)
No. % No. %
Median age (range) 63 (40–83) 65 (23–85)
Sex
Male 93 71 96 73
Female 38 29 35 27
ECOG performance status score
0 97 74 91 69
1 34 26 40 31
Adjuvant chemotherapy 37 28 37 28
Clinically significant comorbidities 76 58 65 50
Response to first-line treatment
CR/PR 81 62 77 59
SD 50 38 54 41
Duration of first-line treatment
16–20 weeks 84 64 91 69
21–24 weeks 47 36 40 31
First-line chemotherapy regimen
Irinotecan + fluoropyrimidine 41 31 42 32
Oxaliplatin + fluoropyrimidine 81 62 82 63
Fluoropyrimidine alone 9 7 7 5
Metastatic spread
1 organ 49 37 46 35
>1 organ 82 63 85 65
CR, complete response; PR, partial response; SD, stable disease.
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Figure 1. Kaplan–Meier curves for time to progression from randomiza-
tion. BEV, bevacizumab.
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There was no statistically signiﬁcant difference in the median
OS: 25.4 (95% CI 22.2–28.9) months in the bevacizumab con-
tinuation arm versus 23.8 (95% CI 21–26.8) months in the no
bevacizumab continuation arm (HR 0.83; 95% CI 0.63–1.1;
P = 0.19) (Figure 3). At the time of the analysis, 99 patients
(76%) with bevacizumab continuation and 98 (75%) without
continuation had died. The median PFS, as measured from the
start of ﬁrst-line treatment, was 9.5 months in the bevacizumab
continuation arm (95% CI 8.6–10.2 months) versus 8.5 (95% CI
8–8.9) months in the no bevacizumab continuation arm (HR
0.75; 95% CI 0.59–0.97; P = 0.025) (supplementary Figure S2,
available at Annals of Oncology online).
In a post hoc analysis, the types of PD were grouped into three
categories: new tumour lesions, progression of existing lesions
or a mixture of both. The proportion of patients with PD based
on new lesions (28% versus 27%) and PD based on existing
lesions (40% versus 37%) were similar for the bevacizumab con-
tinuation arm and the no continuation arm.
The times between randomization and start of second-line
treatment were not statistically different (HR 0.82, 95% CI 0.64–
1.06 months; P = 0.14) between the bevacizumab continuation
arm (median 5.9 months, 95% CI 4.8–7.5 months) and the no
bevacizumab continuation arm (median 4.8 months, 95% CI 4.1–
5.5 months) (supplementary Figure S3, available at Annals of
Oncology online). After PD, 114 (87%) of patients in the bevaci-
zumab continuation arm and 115 (88%) in the no bevacizumab
continuation arm were given one or more subsequent anticancer
treatments. Thirty-ﬁve patients (27%) in the bevacizumab con-
tinuation arm and 53 patients (40%) in the no bevacizumab
continuation arm received further bevacizumab treatment.
safety
During the trial period, most adverse events (AEs) were grade 1
or 2, whereas eight patients (6%) in the bevacizumab continu-
ation arm versus one patient (1%) in the no maintenance arm
experienced a grade ≥3 AE (Table 2). The most common grade
≥3 AE was hypertension (6 versus 1 patients). There were no
drug-related deaths during the trial phase.
cost analysis
The mean cost per patient in the bevacizumab continuation arm
was 37 596 USD (range 4794–229 038 USD) versus 8180 USD
(range 330–83 465 USD) in the no bevacizumab arm (P < 0.001;
univariate Wilcoxon rank-sum test). Gender- and age-adjusted
cost per patient in the bevacizumab continuation arm was
36 620 USD (95% CI 30 840–43 484) compared with 7882 USD
(95% CI 6636–9363) in the no bevacizumab arm (P < 0.001;
supplementary Table S2, available at Annals of Oncology
online).
Neither age nor gender had a signiﬁcant effect on costs. Costs
per month until progression were also signiﬁcantly different
between treatment arms [bevacizumab continuation arm 5883
USD/month (range 178–15 882), versus no bevacizumab arm
2063 USD/month (range 73–20 493; supplementary Table S2,
available at Annals of Oncology online)]. In the multivariable
gender- and age-adjusted model, age but not gender had a sig-
niﬁcant effect on costs/month, showing a decrease in costs with
increasing age. Using low or high cost estimations in the cost
calculations for control visits to oncologist and hospitalizations
conﬁrmed the results for the base case analyses.
All Hazard ratio (95% CI)
Female
Male
WHO 0
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Figure 2. Hazard ratios and 95% conﬁdence intervals for time to progres-
sion by patient subgroup. BEV, bevacizumab.
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Figure 3. Kaplan–Meier curves for overall survival from start of ﬁrst-line
therapy. BEV, bevacizumab.
Table 2. Pre-specified adverse events associated with bevacizumab
(CTCAE 3.0)
Patients (%) Bevacizumab
continuation (n = 131)
No bevacizumab
continuation (n = 131)
Grade
1–2
Grade
3–4
Grade
5
Grade
1–2
Grade
3–4
Grade
5
Haemorrhage 5 — — 1 — —
Hypertension 15 6 — 3 1 —
Proteinuria 15 — — 1 — —
Thrombosis — 2 — — — —
GI perforation — — — — — —
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discussion
Bevacizumab is an important addition to the range of chemo-
therapy drugs that are currently used for the treatment of
mCRC. The magnitude of beneﬁt derived from bevacizumab in
ﬁrst-line treatment of mCRC appears to some degree to depend
on the backbone chemotherapy regimen used [8], although the
monoclonal antibody is most often combined with classical
chemotherapy regimens like FOLFOX or FOLFIRI.
Until recently, bevacizumab infusions were continued until
disease progression, even if chemotherapy has been interrupted
earlier for any reason during ﬁrst-line treatment, as it is assumed
that bevacizumab monotherapy might be sufﬁcient to prolong
disease control achieved with combination induction therapy. In
second-line treatment, however, bevacizumab as a single agent
has very little activity [5]. As the optimal duration of bevacizumab
during the course of ﬁrst-line treatment has not been investigated
before in randomized trials, we considered bevacizumab continu-
ation to be a commonly used treatment strategy in clinical prac-
tice according to the overall respected treatment preference,
which was inﬂuenced by the registration trial of bevacizumab [2]
and the Swiss drug labelling of bevacizumab, which recommends
bevacizumab continuation until disease progression. In our trial,
the arm with the treatment holidays strategy [9, 10] was chosen as
comparator.
A non-inferiority margin of a 6-week difference in TTP
between bevacizumab continuation and no continuation was
selected, in consultation with expert oncologists. Non-inferiority
was not demonstrated in this trial, as the non-inferiority margin
lies within the conﬁdence interval for the HR. The observed dif-
ference in the median TTP of 5 weeks between the two treatment
arms is below the chosen margin of a 6-week difference and indi-
cates a difference of modest magnitude. This notion is further
supported by a median difference of only 4 weeks in PFS.
There was no general consensus regarding the deﬁnition of a
valid surrogate end point for OS when this trial was planned.
Potential surrogate end points for OS include PFS or TTP. PFS
differs from TTP in that PFS includes death as a result of any
cause in its deﬁnition in addition to progression and appears as
a more appropriate end point, because it is stronger associated
with OS than TTP [11].
Detecting small differences in time-to-event end points such as
TTP or PFS requires very close intervals between tumour assess-
ments and/or a very large sample size. However, small differences
in TTP or PFS become clinically meaningless in the context of an
incurable disease unless OS is impacted. The survival analysis
indicates a small, consistent but statistically non-signiﬁcant trend
towards longer OS in the bevacizumab continuation arm.
Whether second and subsequent lines of therapy, which were
very balanced between both arms, or the later use of bevacizu-
mab, had any substantial impact on this secondary end point
remains speculative but unlikely.
The disease progression patterns after cessation of bevacizu-
mab therapy did not differ between treatment arms, in line with
earlier observations [12].
Besides the selection requirement to achieve at least SD fol-
lowing induction therapy, a broad spectrum of patients, all with
disease not amenable to curative surgery, was included into this
trial. Patients were not selected by molecular markers, as
cetuximab became available only 1 year before trial recruitment
was completed. At that time, 80% of patients had already been
recruited. We assume that RAS and BRAF mutations were dis-
tributed similarly in both arms.
Different chemotherapy regimens were used during induction
treatment. This reﬂects the heterogeneity in clinical practice
during the study period. To avoid potential imbalances between
treatment arms, we used the chemotherapy backbones as strati-
ﬁcation factors.
As demonstrated in another trial with mCRC patients [7],
single-agent bevacizumab is associated with a low incidence of
treatment-related severe adverse effects. No fatalities due to tox-
icity occurred. Low-grade adverse events were noticeably more
frequent in the bevacizumab continuation arm. A quality-of-life
assessment was not part of our trial, as we did not anticipate
detecting meaningful differences.
We assessed the time interval between randomization and start
of second-line treatment. Again we observed a minor and statis-
tically non-signiﬁcant difference for this end point between the
two arms. Although the decision to start a new line of treatment
and its timing are somewhat arbitrary and depend on many
factors, it is interesting to note that there was a delay of nearly 2
months between the median TTP and this end point. Thus, diag-
nosing progressive disease does not necessarily trigger the imme-
diate need for a new line of cancer treatment in all patients.
Oncology is becoming an increasingly value-based specialty
[13]. Whereas incremental cost utility ratios using a lifelong
quality-of-life-adjusted time horizon are preferred in health eco-
nomic analyses [14], data required for such analyses are not
always fully available. We used approximate unit costs for our
analysis and found a difference of ∼30 000 USD between bevaci-
zumab continuation versus no continuation in the mean costs
per patient until disease progression.
The rapid onset of drug resistance and subsequent treatment
failure with bevacizumab monotherapy reinforces the need for
alternative strategies. One approach is to offer patients a treat-
ment-free interval, although criteria to select patients for this
strategy are not known at this time. Another is to de-escalate in-
duction chemotherapy and continue one component (usually
ﬂuoropyrimidines) in combination with bevacizumab, as shown
to be effective in the CAIRO-3 trial [15]. Additional evidence
regarding this latter approach comes from a recently reported
three-arm randomized trial comparing no maintenance treat-
ment versus bevacizumab continuation versus a combination of
capecitabine and bevacizumab in patients who had completed
induction chemotherapy [16]. In this non-inferiority trial,
which enrolled 840 patients to induction chemotherapy plus
bevacizumab, 473 patients were randomized after 6 months of
induction treatment. The primary end point of this trial was
‘time to failure of strategy’ (TFS), comprising maintenance plus
re-induction after ﬁrst progression. The difference in the
median PFS between bevacizumab alone versus no treatment
until disease progression was 4 weeks (4.6 versus 3.6 months),
which conﬁrms the results of our trial. Continuing single-agent
chemotherapy plus bevacizumab achieved a median PFS of 6.2
months. The PFS in the chemotherapy plus bevacizumab main-
tenance arm was signiﬁcantly longer compared with the no
treatment arm. This advantage in PFS however did not translate
into a signiﬁcantly prolonged survival in this trial.
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In summary, we found no evidence that continuation of beva-
cizumab as a single agent after completion of ﬁrst-line chemo-
therapy appears is of meaningful therapeutic value. Today’s
treatment preference for maintenance therapy, based on current
knowledge, is to continue with ﬂuoropyrimidines alone or in
combination with bevacizumab, or to offer treatment holidays.
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